ReviewTranslational vision science & technology2025
Blood-Based Cell-Free DNA in Ophthalmic Oncology.
Review in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biopsy of Iris and Anterior Chamber Tumours: Fine Needle, Minimally Invasive and Excision Techniques - Review.Clinical & experimental ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Purpose: Cell-free DNA (cfDNA) has emerged as a useful liquid biopsy biomarker with many translational applications in oncology. Here, we review the uses of blood-based cfDNA in ophthalmic oncology, with a focus on uveal melanoma, retinoblastoma, conjunctival tumors, choroidal metastases, indeterminate choroidal lesions, and ocular histiocytosis. Methods: A systematic literature search in MEDLINE, PubMed, Web of Science, and Scopus from October 2017 to June 2025 was performed. Data extraction included tumor diagnosis, number of patients in the cohort, characteristics of the blood-based cfDNA assay employed (including technology used for mutation identification), number and types of genes analyzed, performance metrics for the assay, and any clinical impact. Results: The use of blood-based cfDNA in the field of ophthalmic oncology has been studied to varying degrees. Perhaps its most well-researched area is uveal melanoma, in which applications for both primary and metastatic uveal melanoma continue to be evaluated. Its use in retinoblastoma has been investigated by a small number of groups. There is minimal but intriguing work on the use of blood-based cfDNA in for conjunctival tumors, choroidal metastases, tumors of indeterminate origin, and ocular histiocytosis. Conclusions: cfDNA science bridges the gap between basic research and clinical care. Within the field of ophthalmic oncology, cfDNA may be useful as a diagnostic/prognostic tool, for surveillance of metastatic or minimally residual disease, to identify driver mutations for treatment selection, as a biomarker of treatment response, for screening for recurrent or new cancer, and to detect new molecule clones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.